Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.6
3.4
Journals
JPM
Special Issues
Biomarkers and Personalized Therapies in Pancreatic Cancer
share announcement

Biomarkers and Personalized Therapies in Pancreatic Cancer

A special issue of Journal of Personalized Medicine (ISSN 2075-4426).

Deadline for manuscript submissions: closed (31 October 2019) | Viewed by 12698

Special Issue Editor

Dr. Tracy Putoczki

E-Mail Website
Guest Editor
Personalized Oncology Division, The Walter and Eliza Hall Institute of Medical Research
Interests: cancer; cytokines; inflammation; microenvironment
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Pancreatic cancer is the most lethal of all solid malignancies, with a significant rise in deaths predicted by 2020. Currently, standard-of-care chemotherapeutics remain the best treatment option for patients.

In this Special Issue, emerging opportunities to personalise a patient’s treatment journey will be discussed. These include new strategies to detect the cancer and monitor a patient’s response by a blood test, our evolving understanding of molecular profiles and tumour sub-types, a new understanding of the complex role the tumour microenvironment plays in treatment responses, selection of appropriate patients for targeted therapies, and opportunities to better segregate patients in design clinical trials.

Sincerely,

Dr. Tracy Putoczki
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Circulating tumour (ct) DNA 
  • Immunotherapy 
  • Microbiome 
  • Molecular profiling 
  • Neoadjuvant therapy 
  • Organoid screening 
  • Targeted therapy
  • Tumor microenvironment

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

Jump to: Other

9 pages, 209 KiB  
Review
Clinical Applications of Circulating Tumour DNA in Pancreatic Adenocarcinoma
by Matthew Loft, Belinda Lee, Jeanne Tie and Peter Gibbs
J. Pers. Med. 2019, 9(3), 37; https://doi.org/10.3390/jpm9030037 - 18 Jul 2019
Cited by 6 | Viewed by 5933
Abstract
Pancreatic adenocarcinoma remains one of the most aggressive cancers with an ongoing dismal survival rate despite some recent advances in treatment options. This is largely due to the typically late presentation and limited effective therapeutic options in advanced disease. There are numerous circulating [...] Read more.
Pancreatic adenocarcinoma remains one of the most aggressive cancers with an ongoing dismal survival rate despite some recent advances in treatment options. This is largely due to the typically late presentation and limited effective therapeutic options in advanced disease. There are numerous circulating biomarkers that have potential clinical application as tumour markers, including circulating tumour DNA (ctDNA), circulating tumour cells (CTCs), cell-free RNA (cfRNA), exosomes and circulating tumour proteins. This review will focus on the development of ctDNA as a non-invasive liquid biopsy, with its high sensitivity and specificity having potential clinical applications in pancreatic cancer. These include a role in screening, prognostication via the detection of minimal residual disease, early detection of recurrence, and for patients with advanced disease; tumour genotyping and monitoring treatment response. Prospective randomised adjuvant clinical trials are currently underway, exploring the impact of ctDNA-guided adjuvant therapy decisions. In this review, we provide perspectives on the current literature and considerations of future directions. Full article
(This article belongs to the Special Issue Biomarkers and Personalized Therapies in Pancreatic Cancer)

Other

Jump to: Review

13 pages, 777 KiB  
Commentary
Inflammation, Biomarkers and Immuno-Oncology Pathways in Pancreatic Cancer
by Belinda Lee and Peter Gibbs
J. Pers. Med. 2019, 9(2), 20; https://doi.org/10.3390/jpm9020020 - 26 Apr 2019
Cited by 13 | Viewed by 6412
Abstract
It is estimated that pancreatic cancer will be the second leading cause of cancer-related deaths globally by 2030, highlighting the ongoing lack of effective treatment options for this devastating condition. There is a lack of reliable prognostic or predictive markers in pancreatic cancer [...] Read more.
It is estimated that pancreatic cancer will be the second leading cause of cancer-related deaths globally by 2030, highlighting the ongoing lack of effective treatment options for this devastating condition. There is a lack of reliable prognostic or predictive markers in pancreatic cancer to guide management decisions, whether for systemic chemotherapy, molecularly targeted therapies, or immunotherapies. To date, the results for targeted agents and immunotherapies in unselected populations of chemo-refractory pancreatic cancer have not met expectations. The reasons for this lack of efficacy of immunotherapy in pancreatic cancer are not completely understood. The challenges in pancreatic cancer include the physical barrier created by the dense desmoplastic stroma surrounding the tumor, chemokine-mediated exclusion of T cells, relatively poorer antigenicity compared to other solid tumors, paucity of infiltrating T cells within the tumor, ultimately leading to an immunosuppressive microenvironment. A better understanding of the role of inflammation in pancreatic cancer, its tumor microenvironment and individualized patient-related features, be they molecular, clinical or histopathological, would enable a more effective tailored approach to the management of pancreatic cancer. In this review, the role of inflammation, the immune tumor microenvironment and potential immune biomarkers in pancreatic cancer are explored. Full article
(This article belongs to the Special Issue Biomarkers and Personalized Therapies in Pancreatic Cancer)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop